Pfizer and biontech choose lead mrna vaccine candidate against covid-19 and commence pivotal phase 2/3 global study

Pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced the start of a global (except for china) phase 2/3 safety and efficacy clinical

BNTX Ratings Summary

BNTX Quant Ranking